The EAU’s premier robotic urology event has started. Not in Düsseldorf as originally intended (and long hoped for), but as a two-day virtual event. The EAU Robotic Urology Section has years, if not decades, of experience with live transmissions of surgery from all across the world so it was well prepared for holding a virtual […]
γ-Glutamyltransferase is reportedly associated with survival in local and metastatic renal cell carcinoma patients; however, its predictive role among patients treated with immune-checkpoint inhibitors are unknown.
Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab have improved outcomes in metastatic renal cell carcinoma (mRCC) patients, but they are also associated with immune-related adverse events (irAEs).
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are being increasingly defined. The TRACERx Renal studies and others that have described the interaction between tumour genomics and remodelling of the tumour microenvironment provide important new insights into the molecular drivers underlying ccRCC ontogeny and progression.
Worldwide, prostate cancer is considered to be one of the three most commonly occurring cancers amongst the male population. Clinically, early detection of diverse forms of cancer before they spread and become incurable plays an important role in treatment strategy.
Men treated for localized prostate cancer by radiotherapy have often a remaining life span of 10 yr or more. Therefore, the risk for secondary malignancies should be taken into account. Plans for ten patients were evaluated which had been performed on an Oncentra® treatment planning system for a treatment with an Elekta Synergy™ linac with Agility™ […]
Urinary incontinence (UI) is one of the main complications of radical prostatectomy. Multiple studies have attempted to find factors that may predict early recovery of urinary continence in surgically treated patients.
During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic.
The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and taxane.
The 2012 US Preventive Services Task Force (USPSTF) recommendation against routine prostate-specific antigen (PSA) testing led to a decrease in prostate cancer screening, but the heterogeneity of its impact by race/ethnicity remains unclear.
